Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Altamira Therapeutics Ltd CYTOF

Healthcare Biotechnology
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery... see more

Recent & Breaking News (OTCQB:CYTOF)

Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo

Accesswire February 14, 2022

Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets

Accesswire February 9, 2022

Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries

Accesswire February 7, 2022

Altamira Therapeutics Establishes OTC Consumer Health Business Unit

Accesswire February 4, 2022

Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia

Accesswire January 21, 2022

Altamira Therapeutics Provides Update on RNA Therapeutics Program

Accesswire January 13, 2022

Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

Accesswire January 5, 2022

Altamira Therapeutics Provides Update on Bentrio Program

Accesswire December 29, 2021

Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy

Accesswire December 16, 2021

Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis

Accesswire December 1, 2021

Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021

Accesswire November 15, 2021

Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant

Accesswire November 12, 2021

Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets

Accesswire October 25, 2021

Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application

Accesswire October 14, 2021

Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference

Accesswire October 6, 2021

Altamira Therapeutics Provides Update on Bentrio Program

Accesswire September 27, 2021

Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program

Accesswire September 21, 2021

Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Accesswire September 9, 2021

Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results

Accesswire September 8, 2021

Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC

GlobeNewswire October 11, 2017